Brief: Antengene Corp Says Approval Of NDA By Malaysian National Pharmaceutical Regulatory Agency
05/08/2024 16:07
Aug 5 (Reuters) - Antengene Corporation Ltd 6996.HK :
* APPROVAL OF NDA BY MALAYSIAN NATIONAL PHARMACEUTICAL
REGULATORY
AGENCY FOR XPOVIO FOR TWO INDICATIONS
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106